Critical Comparison: Scienture (NASDAQ:SCNX) versus Surrozen (NASDAQ:SRZN)

Surrozen (NASDAQ:SRZN) and Scienture (NASDAQ:SCNX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Valuation & Earnings

This table compares Surrozen and Scienture”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$12.62 million	9.35	-$63.56 million	($14.42)	-0.95
Scienture	$140,000.00	128.38	$9.07 million	N/A	N/A

Scienture has lower revenue, but higher earnings than Surrozen.

Risk & Volatility

Surrozen has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Scienture has a beta of 3.11, meaning that its stock price is 211% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Surrozen and Scienture, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	0	0	2	0	3.00
Scienture	0	0	0	0	0.00

Surrozen currently has a consensus target price of $38.50, suggesting a potential upside of 179.59%. Given Surrozen’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Surrozen is more favorable than Scienture.

Institutional & Insider Ownership

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 5.7% of Scienture shares are owned by institutional investors. 45.2% of Surrozen shares are owned by insiders. Comparatively, 49.7% of Scienture shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Surrozen and Scienture’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Surrozen	-274.42%	-545.43%	-64.40%
Scienture	-10,364.22%	-24.47%	-19.30%

About Surrozen

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

About Scienture

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.